StockData
Viatris Inc logo

Viatris Inc (VTRS) stock

VTRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/303% below fair value
$19.63−0.25 (-1.26%)

Close on Nov 20, 2026Market cap $22.55BP/E –Yield 2.45%

Viatris gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Viatris's gross profit for the twelve months ending Jun 30, 2026 was $5.13B, down 0.7% year over year. For fiscal 2025 it was $5.01B, down 10.8% from the year before. The highest annual figure on record is $6.50B in fiscal 2022.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$5.01B-10.8%
FY2024Dec 31, 2024$5.62B-12.7%
FY2023Dec 31, 2023$6.44B-0.9%
FY2022Dec 31, 2022$6.50B+16.5%
FY2021Dec 31, 2021$5.58B+46.9%
FY2020Dec 31, 2020$3.80B-2.6%
FY2019Dec 31, 2019$3.90B-2.6%
FY2018Dec 31, 2018$4.00B–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.46B+9.3%
Q1 FY2026Mar 31, 2026$1.16B-0.3%
Q4 FY2025Dec 31, 2025$1.15B-5.5%
Q3 FY2025Sep 30, 2025$1.37B-6.0%
Q2 FY2025Jun 30, 2025$1.33B-7.8%
Q1 FY2025Mar 31, 2025$1.16B-22.8%
Q4 FY2024Dec 31, 2024$1.22B-23.9%
Q3 FY2024Sep 30, 2024$1.46B-13.7%
Q2 FY2024Jun 30, 2024$1.45B-10.1%
Q1 FY2024Mar 31, 2024$1.50B-2.5%
Q4 FY2023Dec 31, 2023$1.60B+25.3%
Q3 FY2023Sep 30, 2023$1.69B-3.3%
Q2 FY2023Jun 30, 2023$1.61B-5.6%
Q1 FY2023Mar 31, 2023$1.54B-12.9%
Q4 FY2022Dec 31, 2022$1.27B-17.6%
Q3 FY2022Sep 30, 2022$1.75B+11.1%
Q2 FY2022Jun 30, 2022$1.70B+28.3%
Q1 FY2022Mar 31, 2022$1.77B+57.1%
Q4 FY2021Dec 31, 2021$1.55B+118.9%
Q3 FY2021Sep 30, 2021$1.57B+35.9%
Q2 FY2021Jun 30, 2021$1.33B+29.4%
Q1 FY2021Mar 31, 2021$1.13B+24.4%
Q4 FY2020Dec 31, 2020$706.40M–
Q3 FY2020Sep 30, 2020$1.16B–
Q2 FY2020Jun 30, 2020$1.03B–
Q1 FY2020Mar 31, 2020$906.10M–

More Viatris figures

See a number that looks wrong?